Results 151 to 160 of about 3,302 (197)

Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study

United European Gastroenterology journal
Background Janus kinase (JAK) inhibitors, filgotinib (FIL) and upadacitinib (UPA) have emerged as promising treatments for ulcerative colitis (UC). However, a comparative analysis of these JAK inhibitors, particularly in patients previously treated with ...
A. Nogami, K. Asonuma, Shinji Okabayashi, Maiko Ikenouchi, Takahisa Matsuda, S. Shinzaki, M. Fukata, Taku Kobayashi   +7 more
semanticscholar   +1 more source

P0611 Effectiveness comparisons between tofacitinib, filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study

Journal of Crohn's & Colitis
As no direct comparisons exist, we compared the effectiveness of tofacitinib (TOFA), filgotinib (FILGO) and upadacitinib (UPA) in patients with Ulcerative Colitis (UC).
A. Buisson, X. Treton, M. Nachury, M. Uzzan, G. Bouguen, A. Banana Hamadidi, A. Amiot, M. Serrero, M. Fumery, L. Caillo, M. Hupé, B. Pereira, R. Altwegg   +12 more
semanticscholar   +1 more source

P0662 Comparative effectiveness and safety of upadacitinib, tofacitinib, and filgotinib in patients with Ulcerative Colitis: analysis of whole and propensity score-matched data

Journal of Crohn's & Colitis
Moderate-to-severe Ulcerative Colitis (UC) often requires advanced treatments. Janus kinase (JAK) inhibitors, upadacitinib, tofacitinib, and filgotinib, have demonstrated efficacy in UC, though real-world comparisons remain limited.
L. Bertin, D. Scarabello, F. Zingone, E. Savarino, B. Barberio   +4 more
semanticscholar   +1 more source

Efficacy of Filgotinib in Moderate to Severe Ulcerative Colitis: A Prospective Study Using Partial Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, and Geboes Histopathology Score

Crohn's & Colitis 360
Background/Aims Filgotinib (FIL), a Janus kinase inhibitor, shows clinical efficacy in moderate to severe ulcerative colitis (UC), but no prospective studies have examined endoscopic and histopathological outcomes.
Yoshiyuki Shirouzu, Hideki Ishibashi, Masayoshi Kage, Yutaro Mihara, Yuka Sakakibara, Kazuyoshi Nagata, Asami Suzuki, Toshihiro Ohmiya, Tomoko Irie, Yasumi Araki, K. Mitsuyama, H. Takedatsu, T. Noake   +12 more
semanticscholar   +1 more source

P0849 Real-world efficacy and safety of filgotinib in ulcerative colitis: results from the ENEIDA registry

Journal of Crohn's & Colitis
Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by periods of relapse and remission. Current treatment options aim to achieve mucosal healing and sustain long-term remission, yet many patients experience treatment failure ...
I. Rodríguez-Lago, L. Cudero, C. Martínez Pascual, A. Minguez, R. Ferreiro-Iglesias, L. Arranz, A. Royo, D. Martín-Rodríguez, M. L. Mejías, M. Calafat, M. Calvo, C. Gargallo-Puyuelo, A. Granja, J. Santos-Fernández, P. Ucha, D. Ceballos, M. Martín-Arranz, I. Ferrer, L. Ramos, P. Almela, A. Fernández-Clotet, O. García-Bosch, J. Huguet, M. Lozano, S. Riestra, E. Sesé, G. Torres, A. M. Trapero, P. Varela, E. Domènech, M. Barreiro‐de Acosta   +30 more
semanticscholar   +1 more source

P1140 Filgotinib effectiveness and safety in moderate and severely active patients with Ulcerative Colitis: early real-world outcomes in an interim analysis of data from the prospective, observational GALOCEAN study

Journal of Crohn's & Colitis
A post hoc analysis of the SELECTION trial (NCT02914522) showed that patients with moderately active Ulcerative Colitis (UC) were more likely to respond to filgotinib (FIL), a once-daily, oral Janus kinase 1 preferential inhibitor, than those with ...
J. Seenan, M. Høivik, S. Vermeire, S. Schreiber, W. Reinisch, M. Löwenberg, G. Doherty, C. Gilletta de Saint Joseph, E. Ricart, R. Saldaña, W. Sawyer, O. Bouzid, C. Rudolph, A. Armuzzi   +13 more
semanticscholar   +1 more source

P110 Baseline characteristics, disease activity, patient-reported outcomes and safety in patients with rheumatoid arthritis treated with filgotinib in the UK: up to 1-year interim results from FILOSOPHY

Rheumatology
FILOSOPHY (NCT04871919) is an ongoing, prospective, observational real-world European study of filgotinib for RA. We report up to 1-year interim data from UK patients.
Muhammad K. Nisar, Smita Bhat, O. Bouzid, Tariq Daud, Thomas P A Debray, James B Galloway, Neil D Mckay, Lindsay Robertson, H. Tahir   +8 more
semanticscholar   +1 more source

P1160 Real-world comparative safety of filgotinib and upadacitinib for ulcerative colitis: a propensity score matching

Journal of Crohn's & Colitis
We previously reported that upadacitinib (UPA) demonstrated higher effectiveness than filgotinib (FIL) in the treatment of ulcerative colitis (UC) [1]. We aimed to compare safety profiles between FIL and UPA.
A. Nogami, K. Asonuma, S. Okabayashi, M. Ikenouchi, S. Shinzaki, M. Fukata, T. Kobayashi   +6 more
semanticscholar   +1 more source

Simultaneous Quantification of Filgotinib and Its Active Metabolite in Human Plasma Using Liquid Chromatography–Tandem Mass Spectrometry: Validation and Clinical Application

Biomedical chromotography
Filgotinib (FLG) is a Janus kinase 1 inhibitor and is metabolized to an active metabolite, GS‐829845. There is no report on the method for simultaneous quantification of FLG and GS‐829845 in clinical samples.
Takahiro Ito, M. Suno, Minae Shintani, Ayaka Iwata, Takao Fujii, Kazuo Matsubara   +5 more
semanticscholar   +1 more source

P1017 Real-world effectiveness and safety of filgotinib with and without concomitant therapies in patients with Ulcerative Colitis: an interim analysis of the prospective, observational GALOCEAN study

Journal of Crohn's & Colitis
Filgotinib (FIL), a once-daily, oral Janus kinase 1 preferential inhibitor, was approved for the treatment of Ulcerative Colitis (UC) following the phase 2b/3, randomized SELECTION clinical trial.1 Real-world data on the effectiveness and safety of
M. Høivik MD- PhD, S. Vermeire, W. Reinisch, J. Seenan, M. Löwenberg, S. Schreiber, A. Armuzzi, E. Ricart, G. Doherty, R. Saldaña, W. Sawyer, C. Rudolph, A. Jus, C. Gilletta de Saint Joseph   +13 more
semanticscholar   +1 more source